FOXO Technologies Inc. Sets Fourth Quarter and Full Year 2022 Business Update Call for Thursday, March 30, 2023 at 3:15 p.m. CT

Rhea-AI Summary

FOXO Technologies Inc. (AMEX: FOXO) is set to report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 30, 2023. The management will host a conference call at 3:15 p.m. Central time on the same day to discuss these results and recent business updates. Interested parties can access the call via webcast or by dialing in. FOXO specializes in commercializing epigenetic biomarkers to modernize the life insurance industry, employing artificial intelligence to analyze DNA methylation for health and aging insights.

Positive

• Upcoming financial results announcement for Q4 and full year 2022 may provide insight into business growth.
• FOXO's focus on commercializing epigenetic technology positions it uniquely in the life insurance sector.

Negative

• Potential uncertainty around financial performance results may affect investor confidence.

MINNEAPOLIS--(BUSINESS WIRE)-- FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022 after market closes on Thursday, March 30, 2023.

Management will host a conference call to discuss fourth quarter and full year 2022 results and recent business highlights at 3:15 p.m. Central time on Thursday, March 30, 2023.

The call can be accessed via webcast on the investors section of the Company’s website at www.foxotechnologies.com/investors or by dialing (888) 770-7136 and referencing conference ID 4335886. Participants are encouraged to call in 10 to 15 minutes prior to the scheduled start time.

The webcast will be made available for replay on the Company’s website beginning approximately two hours after the event.

About FOXO Technologies Inc. (“FOXO”)

FOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with the FOXO Longevity Report. For more information about FOXO, visit www.foxotechnologies.com. For more information about FOXO Life, visit www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005780/en/

Investor Relations

Matthew Hausch, Cody Slach

Gateway Investor Relations

(949) 574-3860

FOXO@gatewayir.com

Source: FOXO Technologies Inc.

FAQ

When will FOXO Technologies report its financial results?

FOXO Technologies will report its financial results on March 30, 2023, after market close.

What time is the FOXO Technologies conference call?

The conference call is scheduled for 3:15 p.m. Central time on March 30, 2023.

How can I access the FOXO Technologies conference call?

The conference call can be accessed by dialing (888) 770-7136 or via webcast on FOXO's investor website.

What does FOXO Technologies focus on?

FOXO Technologies focuses on commercializing longevity science through epigenetic biomarkers for the life insurance industry.